Social media

The EU Joint Clinical Assessment is already influencing how oncology therapies are developed and assessed across Europe. In this article, Dr. Liz O’Brien of ICON explains how #JCA is driving earlier evidence generation, ...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

A new qualitative study in BMC Musculoskeletal Disorders confirms the content validity of the Oswestry Disability Index instrument for individuals with Degenerative Disc Disease. The research shows high alignment betwe...

A new qualitative study in BMC Musculoskeletal Disorders confirms the content validity of the Oswestry Disability Index instrument for individuals with Degenerative Disc Disease. The research shows high alignment betwe...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® explores the evolving NIT landscape, emerging regulat...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in Select Science explores the evolving NIT landscape, emerging regulat...

In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistical workflows, cut costs and deliver more transparent, scalable analyses. Read more: https://ow.ly/Q1...

In this Journal of mHealth article, Ashish Koul explains how open-source R software empowers CROs to modernise statistical workflows, cut costs and deliver more transparent, scalable analyses. Read more: https://ow.ly/JE...

The EU Joint Clinical Assessment (#JCA), launched in 2025, is reshaping how oncology and #ATMP trials are designed and assessed across Europe. With 27 EU countries plus Norway, Switzerland, Ukraine and the UK now sharing...